NCT07187817 SEquential Treatment of PSoriasis With Biologics
| NCT ID | NCT07187817 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal United Hospitals Bath NHS Foundation Trust |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 366 participants |
| Start Date | 2025-10-14 |
| Primary Completion | 2026-08-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 366 participants in total. It began in 2025-10-14 with a primary completion date of 2026-08-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Psoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases. This study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required
Eligibility Criteria
Inclusion Criteria: * Diagnosis of chronic plaque psoriasis by a Dermatology consultant * Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom Exclusion Criteria: * Diagnosis of other forms of psoriasis for example generalised pustular psoriasis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07187817 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07187817 currently recruiting?
Yes, NCT07187817 is actively recruiting participants. Contact the research team at charlotteelizabeth.gollins@nhs.net for enrollment information.
Where is the NCT07187817 trial being conducted?
This trial is being conducted at Bath, United Kingdom.
Who is sponsoring the NCT07187817 clinical trial?
NCT07187817 is sponsored by Royal United Hospitals Bath NHS Foundation Trust. The trial plans to enroll 366 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.